You are here: Home » Companies » Results
Business Standard

Drug firm Ipca Laboratories fourth quarter profit up 94% at Rs 161 crore

Shares of Ipca Laboratories were trading at Rs 2,132.30 per scrip on BSE, down 3.06 per cent from the previous close.

IPCA Laboratories | Q4 Results | Pharma sector

Press Trust of India  |  New Delhi 

pharmacy, drugs, medicine, pharma companies, pharmaceuticals, vaccine, coronavirus, covid, testing
Representational image

Drug firm on Friday reported 94.09 per cent rise in consolidated net profit at Rs 161.20 crore for March quarter 2020-21 mainly on account of higher sales and reduction in expenses.

The company posted a net profit of Rs 83.05 crore for the same period a year ago, Ipca Labs said in a filing to BSE.

Total income stood at Rs 1,134.58 crore in the quarter under review. It was Rs 1,087.49 crore in March quarter 2019-20, it added.

Total expenses were Rs 939.95 crore in the quarter ended March 31, 2021 as against Rs 972.91 crore in the year-ago period, it said.

For 2020-21, the company posted a net profit of Rs 1,141.14 crore as against Rs 603.56 crore in the previous fiscal year, Ipca Labs said.

Total income during the last financial year was Rs 5,482.83 crore. It was Rs 4,715.71 crore in 2019-20, it added.

In a separate filing, Ipca Labs said its board has approved reappointment of Prashant Godha as Executive Director of the company for a further period of 5 years with effect from August 16, 2021.

Shares of were trading at Rs 2,132.30 per scrip on BSE, down 3.06 per cent from the previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, May 28 2021. 16:07 IST